We focus on metabolic, inflammatory, and renal diseases with high unmet need
We are a research-driven biopharmaceutical company developing innovative oral small-molecule therapies for obesity, chronic kidney disease (CKD), and inflammation-driven disorders. By uniting AI/ML discovery, medicinal chemistry, and translational biology, we design differentiated medicines and progress them efficiently through preclinical development toward first-in-human studies.

Our integrated AI/ML R&D platform accelerates target selection, molecule design, and de-risking, while our Biological Research Platform provides human-relevant in vitro/ex vivo systems and in vivo disease models to generate robust, decision-ready data. This end-to-end approach shortens the path from insight to candidate and keeps patient needs at the center of our work.

Backed by a collaborative network of partners and advisors, we are advancing a next wave of oral therapies aimed at reducing inflammation, restoring metabolic balance, and improving kidney health—to deliver meaningful outcomes for patients worldwide.